Published in Gastroenterology on February 01, 1984
Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol (2005) 5.62
Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut (2004) 5.32
Guidelines for the management of inflammatory bowel disease in adults. Gut (2004) 4.15
Crohn's disease and the mycobacterioses: a review and comparison of two disease entities. Clin Microbiol Rev (1989) 3.67
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut (1992) 2.71
A simple method for assessing intestinal inflammation in Crohn's disease. Gut (2000) 2.69
Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut (2001) 2.56
Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut (1996) 2.23
Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut (1994) 2.06
Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut (1992) 1.60
Faecal alpha-1-antitrypsin and excretion of 111indium granulocytes in assessment of disease activity in chronic inflammatory bowel diseases. Gut (1987) 1.54
Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol (2008) 1.52
Factors affecting recurrence after surgery for Crohn's disease. World J Gastroenterol (2005) 1.51
Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver (2010) 1.51
Mesalazine as a maintenance treatment in Crohn's disease: is it the long awaited solution? Gut (1997) 1.38
Ten years' experience with an elemental diet in the management of Crohn's disease. Gut (1990) 1.37
Controlled trial comparing prednisolone with an elemental diet plus non-absorbable antibiotics in active Crohn's disease. Gut (1985) 1.35
Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut (1997) 1.30
Diagnosis and management of fistulizing Crohn's disease. Nat Clin Pract Gastroenterol Hepatol (2009) 1.25
Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut (1996) 1.25
Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation. Gut (1990) 1.24
Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Gut (2003) 1.24
Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut (1996) 1.22
Risks of intestinal anastomoses in Crohn's disease. Ann Surg (1991) 1.20
Effect of glucocorticoids on rectal transport in normal subjects and patients with ulcerative colitis. Gut (1986) 1.19
Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut (2002) 1.17
Rheumatic manifestations of inflammatory bowel disease. World J Gastroenterol (2009) 1.16
Treatment of non-steroidal anti-inflammatory drug induced enteropathy. Gut (1990) 1.14
Technetium-99m hexamethyl propylene amine oxime granulocyte scintigraphy in Crohn's disease: diagnostic and clinical relevance. Gut (1993) 1.13
Update on Anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J Gastroenterol (2007) 1.06
Sulphasalazine: a review of 40 years' experience. Drugs (1986) 1.01
Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut (1997) 1.00
Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Therap Adv Gastroenterol (2011) 0.99
Anti-TNF strategies in stenosing and fistulizing Crohn's disease. Int J Colorectal Dis (2004) 0.98
Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone. Gut (1993) 0.98
Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut (2004) 0.97
Fluticasone propionate in Crohn's disease. Gut (1991) 0.96
Epidemiology and clinical course of Crohn's disease: results from observational studies. World J Gastroenterol (2012) 0.95
Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy. Gut (1995) 0.94
Oxidative DNA damage and antioxidant activity in patients with inflammatory bowel disease. Dig Dis Sci (2007) 0.94
Role of diet in the management of inflammatory bowel disease. World J Gastroenterol (2010) 0.94
Pancreatic autoantibodies in Crohn's disease: a family study. Gut (1997) 0.94
Possible role of MDR1 two-locus genotypes for young-age onset ulcerative colitis but not Crohn's disease. Eur J Clin Pharmacol (2007) 0.92
Does food affect acute inflammatory bowel disease? The role of parenteral nutrition, elemental and exclusion diets. Gut (1986) 0.92
Use of the Crohn's disease activity index in clinical trials of biological agents. World J Gastroenterol (2008) 0.92
Does polymeric formula improve adherence to liquid diet therapy in children with active Crohn's disease? Arch Dis Child (2007) 0.92
Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol (2007) 0.91
Anti-Galectin-3 IgG autoantibodies in patients with Crohn's disease characterized by means of phage display peptide libraries. J Clin Immunol (2001) 0.89
Limitations in assessment of mucosal healing in inflammatory bowel disease. World J Gastroenterol (2010) 0.88
High levels of glucocorticoid receptors in patients with active Crohn's disease may predict steroid resistance. Clin Exp Immunol (2005) 0.86
Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group. Gut (1998) 0.86
Infliximab extends the duration until the first surgery in patients with Crohn's disease. Biomed Res Int (2013) 0.85
Antibodies to colonic epithelial cells from the serum and colonic mucosal washings in ulcerative colitis. Gut (1995) 0.84
New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut (2002) 0.84
Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease. World J Gastroenterol (2011) 0.83
Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: responders versus nonresponders. World J Gastroenterol (2006) 0.83
Clinical outcomes and predictive factors for response after the first course of corticosteroid therapy in patients with Crohn's disease. Gut Liver (2013) 0.83
Controlled trial of oligopeptide versus amino acid diet in treatment of active Crohn's disease. Gut (1995) 0.82
Second Korean guidelines for the management of Crohn's disease. Intest Res (2017) 0.82
High-utilizing Crohn's disease patients under psychosomatic therapy. Biopsychosoc Med (2008) 0.82
Conventional therapy for Crohn's disease. World J Gastroenterol (2006) 0.82
NOD2 polymorphism predicts response to treatment in Crohn's disease--first steps to a personalized therapy. Dig Dis Sci (2011) 0.82
Incidence and risk factors for lymphoma in a single-center inflammatory bowel disease population. Dig Dis Sci (2010) 0.81
Serum antibodies to Mycobacterium avium subspecies paratuberculosis combined with anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients: prevalence and diagnostic role. Dig Dis Sci (2011) 0.81
Total parenteral nutrition as primary treatment in Crohn's disease--RIP? Gut (1988) 0.81
Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease. World J Gastroenterol (2009) 0.80
Controversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approach. World J Gastroenterol (2008) 0.80
Evaluation of "top-down" treatment of early Crohn's disease by double balloon enteroscopy. World J Gastroenterol (2014) 0.80
Analysis of the therapeutic efficacy of different doses of budesonide in patients with active Crohn's ileocolitis depending on disease activity and localization. Int J Colorectal Dis (2003) 0.79
Hydrogen peroxide enhanced ultrasound- fistulography in the assessment of enterocutaneous fistulas complicating Crohn's disease. Gut (1999) 0.79
NOD2 exonic variations in Iranian Crohn's disease patients. Int J Colorectal Dis (2011) 0.79
NOD2/CARD15 gene polymorphism in patients with inflammatory bowel disease: is Hungary different? World J Gastroenterol (2005) 0.78
Role of conventional therapies in the era of biological treatment in Crohn's disease. World J Gastroenterol (2011) 0.78
Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid- and biologics-naïve Japanese patients with early-diagnosed Crohn's disease. BMC Gastroenterol (2014) 0.78
The two sides of the coin: Similarities and differences in the pathomechanisms of fistulas and stricture formations in irritable bowel disease. United European Gastroenterol J (2016) 0.77
Change in the treatment strategy for pediatric Crohn's disease. Korean J Pediatr (2010) 0.77
Surgical strategies in paediatric inflammatory bowel disease. World J Gastroenterol (2015) 0.77
Postheparin plasma diamine oxidase values in the follow up of patients with small bowel Crohn's disease. Gut (1991) 0.77
Medical Therapy of Perianal Crohn's Disease. Viszeralmedizin (2015) 0.76
Medical Therapy of Crohn's Disease. Curr Treat Options Gastroenterol (2005) 0.76
Medical management of Crohn's disease. Clin Colon Rectal Surg (2007) 0.76
Activation of nuclear factor kappaB as a target for anti-inflammatory therapy. Gut (1999) 0.76
Targeting tissular immune response improves diagnostic performance of anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease. PLoS One (2013) 0.76
Standards of medical treatment and nutrition in Crohn's disease. Langenbecks Arch Surg (2004) 0.75
Medical or surgical treatment for Crohn's disease? Postgrad Med J (1988) 0.75
Segmental variability of glucocorticoid induced electrolyte transport in rat colon. Gut (1991) 0.75
Crohn's disease. BMJ Clin Evid (2011) 0.75
Genetic Polymorphisms of Multidrug Resistance Gene-1 (MDR1/ABCB1) and Glutathione S-Transferase Gene and the Risk of Inflammatory Bowel Disease among Moroccan Patients. Mediators Inflamm (2015) 0.75
Ileal Crohn's disease is best treated by surgery. Gut (2002) 0.75
Intestinal stenosis and perforating complications in Crohn's disease. Int J Colorectal Dis (1993) 0.75
Managing refractory Crohn's disease: challenges and solutions. Clin Exp Gastroenterol (2015) 0.75
Crohn's disease. BMJ Clin Evid (2007) 0.75
Searching for the delta: 5-aminosalicylic Acid therapy for Crohn's disease. Gastroenterol Hepatol (N Y) (2011) 0.75
Genetic Control of Flower Development by Homeotic Genes in Antirrhinum majus. Science (1990) 7.30
Public-health impact of outdoor and traffic-related air pollution: a European assessment. Lancet (2000) 6.95
Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin Exp Immunol (1995) 4.81
Complementary floral homeotic phenotypes result from opposite orientations of a transposon at the plena locus of Antirrhinum. Cell (1993) 4.47
Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology (1992) 4.19
GLOBOSA: a homeotic gene which interacts with DEFICIENS in the control of Antirrhinum floral organogenesis. EMBO J (1992) 3.61
Bracteomania, an inflorescence anomaly, is caused by the loss of function of the MADS-box gene squamosa in Antirrhinum majus. EMBO J (1992) 3.60
Increased consumption of refined carbohydrates in patients with Crohn's disease. Klin Wochenschr (1976) 3.51
Genetic engineering of parthenocarpic plants. Nat Biotechnol (1997) 3.31
The 17-kb Tam1 element of Antirrhinum majus induces a 3-bp duplication upon integration into the chalcone synthase gene. EMBO J (1984) 3.07
Nucleotide sequence of the transposable DNA-element IS2. Nucleic Acids Res (1979) 2.89
Ternary complex formation between the MADS-box proteins SQUAMOSA, DEFICIENS and GLOBOSA is involved in the control of floral architecture in Antirrhinum majus. EMBO J (1999) 2.88
Proton-pump inhibitors or H2-receptor antagonists for Helicobacter pylori eradication-a meta-analysis. Lancet (1996) 2.65
A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med (1994) 2.58
Molecular analysis of instability in flower pigmentation of Antirrhinum majus, following isolation of the pallida locus by transposon tagging. EMBO J (1985) 2.48
Comparison of enteral nutrition and drug treatment in active Crohn's disease. Results of the European Cooperative Crohn's Disease Study. IV. Gastroenterology (1991) 2.42
Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry (1974) 2.42
Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci (1981) 2.36
Patient's and doctor's delay in primary breast cancer. Prognostic implications. Acta Oncol (1994) 2.27
Endoscopic papillary dilation (EPD) for the treatment of common bile duct stones and papillary stenosis. Endoscopy (1983) 2.05
[Are proton pump inhibitors superior to H2 receptor antagonists within the scope of H. pylori eradication therapy? Meta analysis of current parallel group comparisons]. Z Gastroenterol (1996) 2.04
Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol (2000) 1.99
Multiple interactions amongst floral homeotic MADS box proteins. EMBO J (1996) 1.96
Mussel Poisoning. Cal West Med (1935) 1.94
Genetic studies of the lac repressor. IX. Generation of altered proteins by the suppression of nonsence mutations. J Mol Biol (1979) 1.88
PLENA and FARINELLI: redundancy and regulatory interactions between two Antirrhinum MADS-box factors controlling flower development. EMBO J (1999) 1.87
The transposable element Tam1 from Antirrhinum majus shows structural homology to the maize transposon En/Spm and has no sequence specificity of insertion. Mol Gen Genet (1991) 1.77
IS1-mediated DNA rearrangements. Cold Spring Harb Symp Quant Biol (1981) 1.68
Integration of IS3 into IS2 generates a short sequence duplication. Mol Gen Genet (1979) 1.49
Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther (1998) 1.47
Segmental portal hypertension. Ann Surg (1986) 1.47
[Consensus report: irritable bowel syndrome--definition, differential diagnosis, pathophysiology and therapeutic possibilities. Consensus of the German Society of Digestive and Metabolic Diseases]. Z Gastroenterol (1999) 1.43
[Paraffin embedding for hemispherial slides within 10 days]. Acta Neuropathol (1967) 1.39
Evaluation of routine upper digestive tract endoscopy before laparoscopic cholecystectomy. Br J Surg (1992) 1.38
The effect of cimetidine on inpatients with duodenal ulcer -- a double blind trial. Acta Gastroenterol Belg (1979) 1.37
Structural analysis of Tam3, a transposable element from Antirrhinum majus, reveals homologies to the Ac element from maize. Plant Mol Biol (1991) 1.36
Prevention of p.o. clotting of av. cimino fistulae with acetylsalicyl acid. Results of a prospective double blind study. Klin Wochenschr (1974) 1.34
Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid. Agents Actions (1986) 1.29
Helicobacter pylori and the risk of colonic adenomas. Colorectal Adenoma Study Group. Digestion (1999) 1.29
[St. John's wort extract in the ambulatory therapy of depression. Attention and reaction ability are preserved]. Fortschr Med (1993) 1.28
Impact of medical and demographic factors on long-term quality of life and body image of breast cancer patients. Ann Oncol (2003) 1.25
Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36. Regul Pept (1994) 1.25
Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut (1996) 1.25
Altered vagal and intestinal mechanosensory function in chronic unexplained dyspepsia. Gut (1998) 1.21
Immune status in Crohn's disease. V. Decreased in vitro natural killer cell activity in peripheral blood. Clin Exp Immunol (1980) 1.20
IS2-43 and IS2-44: new alleles of the insertion sequence IS2 which have promoter activity. Mol Gen Genet (1979) 1.18
Treatment of acute viral hepatitis with (+)-cyanidanol-3. Lancet (1977) 1.18
Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci (1995) 1.18
Gastrointestinal pH profiles in patients with inflammatory bowel disease. Aliment Pharmacol Ther (1998) 1.17
Oral budesonide for prevention of postsurgical recurrence in Crohn's disease. The IOIBD Budesonide Study Group. Gastroenterology (1999) 1.17
Molecular characterization of two stamen-specific genes, tap1 and fil1, that are expressed in the wild type, but not in the deficiens mutant of Antirrhinum majus. Mol Gen Genet (1991) 1.17
Modulation of intestinal epithelial wound healing in vitro and in vivo by lysophosphatidic acid. Gastroenterology (1999) 1.16
Endoscopic papillary dilatation, a possible alternative to endoscopic papillotomy. Lancet (1982) 1.16
Prokinetics in patients with gastroparesis: a systematic analysis. Digestion (1999) 1.16
Alpha 1-antitrypsin, a reliable endogenous marker for intestinal protein loss and its application in patients with Crohn's disease. Gut (1983) 1.16
Wave of chaos: new mechanism of pattern formation in spatio-temporal population dynamics. Theor Popul Biol (2001) 1.16
Fructose induced depletion of liver adenine nucleotides in man. Horm Metab Res (1971) 1.15
Quality of life influenced by primary surgical treatment for stage I-III breast cancer-long-term follow-up of a matched-pair analysis. Ann Surg Oncol (2001) 1.15
Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut (2001) 1.15
[Dietary habits of patients with ulcerative colitis (author's transl)]. Z Gastroenterol (1979) 1.15
[Elimination of errors caused by turbidity in the determination of protein by the biuret method]. Z Klin Chem Klin Biochem (1968) 1.14
Cloning of the potato virus Y genes encoding the capsid protein CP and the nuclear inclusion protein NIb. Arch Virol (1989) 1.14
NTGLO: a tobacco homologue of the GLOBOSA floral homeotic gene of Antirrhinum majus: cDNA sequence and expression pattern. Mol Gen Genet (1993) 1.14
(+)-Cyanidanol-3 in the treatment of acute viral hepatitis: a randomized controlled trial. Hepatology (1984) 1.12
A new type of IS1-mediated deletion. Mol Gen Genet (1981) 1.11
Functional dyspepsia and irritable bowel syndrome: is there a common pathophysiological basis? Am J Gastroenterol (1997) 1.11
Effect of glyceryl trinitrate on the sphincter of Oddi motility and baseline pressure. Gut (1985) 1.10
Fecal blood loss in patients with colonic polyps: a comparison of measurements with 51chromium-labeled erythrocytes and with the Haemoccult test. Gastroenterology (1982) 1.09
Epidemiology of inflammatory bowel disease in the county of Tübingen (West Germany). Scand J Gastroenterol Suppl (1989) 1.08
[Diagnostic possibilities with the determination of amylase and lipase in body fluids]. Internist (Berl) (1970) 1.08
Dietary fiber and nutrient intake in Crohn's disease. Am J Clin Nutr (1979) 1.07
Dyspepsia in healthy blood donors. Pattern of symptoms and association with Helicobacter pylori. Dig Dis Sci (1994) 1.06
Cholecystokinin-58 is the major circulating form of cholecystokinin in canine blood. J Biol Chem (1987) 1.06
Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2'-deoxyuridylate and methylenetetrahydrofolate. Biochem Biophys Res Commun (1974) 1.05
Alteration of tobacco floral organ identity by expression of combinations of Antirrhinum MADS-box genes. Plant J (1996) 1.04
Effect of cigarette smoking on the course of Crohn's disease. Eur J Gastroenterol Hepatol (1996) 1.03
[Epidemiologic aspects of Crohn regional enterocolitis and ulcerative colitis in Marburg/Lahn (West Germany) between 1962 and 1975]. Z Gastroenterol (1983) 1.03
Action of ethanol and some alcoholic beverages on gastric acid secretion and release of gastrin in humans. Gastroenterology (1987) 1.03
Immune status in Crohn's disease. I. Leukocyte and lymphocyte subpopulations in peripheral blood. Scand J Gastroenterol (1978) 1.02
The behaviour of lymphocytes in the process of target cell destruction in vitro. Exp Cell Res (1968) 1.01
Molecular characterization of the genes pcaG and pcaH, encoding protocatechuate 3,4-dioxygenase, which are essential for vanillin catabolism in Pseudomonas sp. strain HR199. Appl Environ Microbiol (1999) 1.01
Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology (2001) 1.01
Effects of semisynthetic diets on xenobiotic metabolizing enzyme activity and morphology of small intestinal mucosa in humans. Gastroenterology (1984) 1.00
Impaired small intestinal peristaltic reflexes and sensory thresholds are independent functional disturbances in patients with chronic unexplained dyspepsia. Am J Gastroenterol (1996) 1.00
Human pancreatic secretion and intestinal motility: effects of ileal nutrient perfusion. Am J Physiol (1990) 0.99
Comparative study with ranitidine and cimetidine on gastric secretion in normal volunteers. Gut (1980) 0.99
[Influence of secretin and pancreozymin on secretion of calcium in the human duodenal juice in normal and impaired pancreas function]. Klin Wochenschr (1970) 0.99
Action of atropine on the pancreatic secretory response to secretin before and after cutting the extrinsic nerves of the pancreas in dogs. Gastroenterology (1986) 0.98
Endoscopic and bioptic study of the upper gastrointestinal tract in Crohn's disease patients. Pathol Res Pract (1985) 0.98
Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology (2000) 0.97
Effect of atropine on pancreatic response to HCl and secretin. Am J Physiol (1981) 0.97
The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer (2001) 0.97
Effects of exogenous zinc supplementation on intestinal epithelial repair in vitro. Eur J Clin Invest (2000) 0.97